Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07776691 |
| Title | A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) |
| Acronym | ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04 |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Merck Sharp & Dohme LLC |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | ISR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| MedStar Washington Hospital Center ( Site 0026) | RECRUITING | Washington D.C. | District of Columbia | 20010 | United States | Details |
| Texas Oncology - DFW ( Site 8005) | RECRUITING | Fort Worth | Texas | 76104 | United States | Details |
| Sourasky Medical Center ( Site 1403) | RECRUITING | Tel Aviv | 6423906 | Israel | Details |